ArticleNPJ Parkinson's disease2026
Multiparametric MRI and imaging transcriptomics reveal molecular and cellular correlates of neurodegeneration in experimental Parkinsonism.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple system atrophy (MSA) is an atypical Parkinsonian disorder marked by oligodendroglial α-synucleinopathy and selective neurodegeneration. Although MRI can capture regional atrophy and microstructural alterations in the MSA brain, the molecular substrates underlying these phenotypes remain poorly defined. Imaging transcriptomics provides a computational framework to relate spatial imaging patterns to brain-wide gene expression. While this approach has been applied to human MSA, interpretation is constrained by limited experimental control and a lack of disease-matched molecular validation. Here, we apply imaging transcriptomics in a controlled preclinical setting by integrating high-resolution ex vivo multimodal MRI with transcriptomic mapping in the PLP-αSyn mouse model of MSA. Structural and diffusion MRI revealed distinct patterns of regional atrophy and microstructural abnormalities. Atlas-based analyses associated imaging phenotypes with gene programs related to oligodendrocyte biology, energy metabolism, and neuroinflammation, with modality-specific signatures. These associations were supported by independent RNA-sequencing and showed convergence with human MSA findings. Our work benchmarks MRI-transcriptomic relationships in MSA and provides a translational framework for interpreting imaging biomarkers in synucleinopathies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.